
Targeson Inc (AKA: Targeson LLC) Profile last edited on: 5/14/19
CAGE: 4KT90
UEI:
Business Identifier: Novel contrast agents for use in diagnosis and therapy of cardiovascular disease and tumor growth Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 52
County: San Diego
Congr. District: 52
County: San Diego
Public Profile
Targeson had een involved in development of ultrasound imaging agents for functional and molecular imaging applications in the research market. The firm's core technology platform used gas-encapsulated microspheres that when coated with specific targeting molecules can adhere to molecular markers of disease and then be imaged by ultrasound. This technique could be used in animal models of a wide variety of diseases, such as cancer, heart attack, atherosclerosis and cardiovascular plaque, organ transplant rejection, and inflammatory bowel disease. Initially targeted at the academic research market to generate income enabling the company to leverage the technology for a clinical product development program, the firm's commercial products included: Targestar® P, a non-targeted ultrasound contrast agent designed to enhance and quantify blood flow and vascular function; Targestar P-HF, a perfusion contrast agent specifically designed to be used with high frequency ultrasound scanners; Targestar SA, a targetable ultrasound contrast agent enabling any biotinylated antibody or biomolecule to be coupled to a microsphere, making it suitable for a wide variety of molecular imaging applications including tumor angiogenesis, myocardial infarction, atherosclerotic plaque, thrombosis, organ transplant rejection and inflammatory diseases; Visistar® Integrin, a targeted ultrasound contrast agent coated with a peptide that binds integrin αvβ3; Visistar VEGFR2, a targeted ultrasound contrast agent coated with a VEGFR2 binding ligand, both indicated for molecular imaging of angiogenesis and tumor growth; Visistar VCAM-1, a targeted ultrasound contrast agent indicated for molecular imaging of inflammation; and Targesphereâ¢, a delivery agent for transfection. As of mid 2017, the firm seems to have discontinued operat
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2015 | 1 | NIH | $224,228 | |
Project Title: Scalable Transfection Technology for Lymphocytes | ||||
2014 | 2 | NIH | $1,960,355 | |
Project Title: Ultrasound-Based Molecular Imaging Probe for Imaging Acute Myocardial Syndromes | ||||
2014 | 1 | NIH | $225,000 | |
Project Title: Molecular Imaging of Macrophage Infiltration in Solid Cancers | ||||
2012 | 2 | NIH | $1,533,707 | |
Project Title: Ultrasound Mediated Targeted Therapy For Kidney Disease | ||||
2011 | 1 | NIH | $195,662 | |
Project Title: Contrast Agents For High-Sensitivity Ultrasound Molecular Imaging Of Tumor Angiog |
Key People / Management
Jack Defranco -- President and Chief Executive Officer
Joshua J Rychak -- Cofounder and VP Research and Development
Joshua J Rychak -- Cofounder and VP Research and Development